STAT+: 102 hours of chaos: How SVB’s collapse rattled the biotech industry
Paul Rennert was surprisingly energized after deplaning a transatlantic flight in Boston Thursday evening. He…
Category: biotechnology
STAT+: French pharma Sanofi buys maker of diabetes treatment for $2.9 billion
Sanofi said Monday that it is acquiring Provention Bio, makers of a diabetes treatment, for…
STAT+: Pfizer buys Seagen, maker of targeted cancer drugs, for $43 billion
Pfizer said Monday it is acquiring Seagen, a maker of targeted cancer drugs, for $43…
STAT+: Biogen’s Samantha Budd Haeberlein, an architect of Aduhelm, leaves company
Samantha Budd Haeberlein, the Biogen senior executive who supervised the development and controversial approval of…
STAT+: FDA approves first treatment for Rett syndrome, a genetic neurological disease
The Food and Drug Administration on Friday approved the first treatment for Rett syndrome, a…
STAT+: SVB, biotech’s bank of choice, just failed. It could have ripple effects
Silicon Valley Bank, which does business with roughly half of the nation’s tech and biotech…
Listen: Pharma blockbusters, pandemic policy, & legal chicanery
Is the next Lipitor on the way? When is a pandemic over-over? And what’s a…
STAT+: KKR veteran sets records with $3.9 billion health care fund
The former head of health care investing at private equity giant KKR has set records…
STAT+: 6 things to know about Apellis’ eye drug ahead of FDA decision
The Food and Drug Administration is nearing a decision on the first treatment for geographic…
STAT+: Gene therapy can transform life for people with hemophilia. But some patients don’t want it.
Given everything he’s been through, Bobby Wiseman says he should have been dead instead of…
Federal panel approves plans to safeguard lab-made virus research
A panel of federal advisers voted unanimously Friday to advance a set of proposals to…
STAT+: Legend says its CAR-T outperformed conventional therapy for multiple myeloma
Legend Biotech said Friday that its CAR-T therapy Carvykti kept multiple myeloma patients’ cancer in…
Listen: George Scangos’ retirement, annual Covid vaccines, an Alzheimer’s drug rejection
Who needs an annual Covid jab? Why did the FDA reject an Alzheimer’s treatment? And…
.jpg)
STAT+: Vir CEO George Scangos to retire, after pandemic success
Vir Biotechnology CEO George Scangos said on Wednesday he will retire, ending an itinerant, nearly…
STAT+: Focused exclusively on life sciences, three top investors set out on their own
Almost a year ago, three top investors at Lux Capital and Obvious Ventures announced they…
STAT+: New results show Cassava’s Alzheimer’s drug has placebo-like efficacy
Cassava Sciences had long claimed that its experimental treatment for Alzheimer’s disease was capable of…
Promising gene therapy delivers treatment directly to brain
When Rylae-Ann Poulin was a year old, she didn’t crawl or babble like other kids…
STAT+: Calico looking for new chief scientist after celebrated biologist David Botstein quietly retires
Are you a promising middle or late-career scientist with a desire to extend human lifespan,…
STAT+: Liquid-biopsy firm Grail is spending more than ever lobbying Congress
Grail spent more than $1 million last quarter lobbying Congress, underscoring the urgency of the…
STAT+: Pliant claims early success in hard-to-treat progressive lung disease
Pliant Therapeutics said Sunday that an experimental pill significantly improved lung function in patients with…
STAT+: How one private biotech seized on JPM to emerge from stealth and tell its story
SAN FRANCISCO — The team behind Rezo Therapeutics, a new biotech co-founded by a group…
Is mesothelin a key to tackling solid tumors? Some biotech companies are betting that it is
On Target is a recurring feature from STAT that dives deep into the most promising…
STAT+: FDA rejects Lilly’s bid for accelerated approval for its Alzheimer’s drug
Eli Lilly said Thursday that U.S. regulators had rejected its application seeking accelerated approval for…
Listen: How blockbusters get made, new vaccines for RSV, and mRNA’s Q score
Where do new drugs come from? Does science need billionaires? And do normal people care…
Opinion: Biopharma leaders helped save democracy. Now what?
The rule of law must be upheld for free societies and free markets to flourish,…
In the search for therapies for solid tumors, companies are turning to a novel target: claudin-6
On Target is a recurring feature from STAT that dives deep into the most promising…
STAT+: Moderna says RSV vaccine worked, setting stage for competition with GSK and Pfizer
Moderna’s vaccine against the respiratory syncytial virus, or RSV, reduced the rate of lower respiratory…
STAT+: After four years of big talk, mega startup Sana prepares to deliver some data
SAN FRANCISCO — The last time Sana CEO Steve Harr was here for the J.P….
STAT+: Liquid biopsy study suggests a better way to decide which colorectal cancer patients need chemo
They’re far too small to be seen by even the most sophisticated medical imaging device….
STAT+: Invitae’s new CEO on why the genetic testing firm stopped chasing ‘volume at all costs’
SAN FRANCISCO — Invitae, a Bay Area genetic testing company with a mission to use…
STAT+: Biotech startups are hungry for dollars. Here’s what one pharma executive was looking for at JPM
Marianne De Backer’s iPhone calendar is a solid block of green. De Backer, the head…
‘We become millionaires and we retire babe’: Former Takeda worker and boyfriend accused of $2.3 million scam of drug firm
A high-ranking former technology officer at Takeda Pharmaceutical’s US headquarters in Massachusetts and her boyfriend…
STAT+: Regeneron executive George Yancopoulos admits some regret, but ‘I don’t apologize’
SAN FRANCISCO — George Yancopoulos isn’t apologizing. The president and chief scientist of Regeneron was…
#JPM23 in review, the year ahead, & the merits of Miami
What happened at biotech’s big reunion? Will this year be better than the last? And…
STAT+: BioNTech CEO lays out vision for how mRNA and AI can power personalized medicine
SAN FRANCISCO — When BioNTech was founded in 2008, messenger RNA therapies and vaccines were…
STAT+: Medicare paves the way for CAR-T in doctors offices
WASHINGTON — Medicare officials have taken a step toward making a cutting-edge cancer treatment called…
STAT+: Upstart Element ratchets up race for cheaper DNA sequencing with a $200 genome
SAN FRANCISCO — Decoding the billions of chemical letters that help shape who we are…
STAT+: Still hoping for looser FDA rules, Regeneron says it will test durable antibody for Covid
SAN FRANCISCO — For months, drugmakers have been pleading with regulators to lower the bar…
STAT+: Illumina, the DNA sequencing giant, gives Wall Street bad news
Illumina, the largest maker of DNA sequencing technology, told investors exactly what they didn’t want…
STAT+: FDA’s Califf says congressional report on Aduhelm controversy contained “no surprises”
SAN FRANCISCO – U.S. Food and Drug Administration commissioner Robert Califf doesn’t disagree with the…
STAT+: New Biogen CEO: New drug launches, more cost cuts, but no ‘radical left turns’ needed
SAN FRANCISCO — In some of his first extended comments since taking over as Biogen’s…
.jpg)
STAT+: Novavax replaces CEO, citing need for “fresh perspective”
The vaccine maker Novavax, which has faced several years of dramatic ups and downs around…
STAT+: A flurry of pharma acquisitions kick off JPM week after a slow year for deals
SAN FRANCISCO — Within the first hours of the J.P. Morgan Healthcare Conference, four life…
STAT+: Regeneron’s Eylea sales dip, as competition looms
SAN FRANCISCO — Regeneron said Monday that it collected $1.5 billion in revenues from its…
STAT+: Arrowhead RNA treatment improves liver scarring in patients, but so does a placebo, clouding study results
An experimental RNA treatment reduced liver scarring in half of patients with an inherited disease…
STAT+: BioMarin executives express confidence around hemophilia gene therapy
For years, BioMarin CEO Jean-Jacques “J.J.” Bienaime has been saying that Roctavian — the company’s…
STAT+: Day One says drug shrinks tumors in common pediatric brain cancer, setting up potential approval
Day One Biopharmaceuticals said Sunday that a targeted therapy shrank tumors by at least 50%…
STAT+: Money troubles and M&A: What’s on biotech insiders’ minds ahead of a not-so-celebratory JPM week
SAN FRANCISCO — What should be a triumphant return to the global biotech industry’s biggest…
FDA approves Alzheimer’s drug shown to moderately slow cognitive decline in early stages of the disease
The Food and Drug Administration on Friday approved a new Alzheimer’s disease treatment that moderately…
STAT+: Fate Therapeutics plans mass layoffs, after early end to cell therapy deal with Janssen
SAN DIEGO — Fate Therapeutics, a biotech upstart with big ambitions to use cell-based therapies…